Gedeon Richter Provides Patient Information for Стопдиар

Gedeon Richter Plc. has released patient information concerning its medication Стопдиар, which contains the active substance nifuroxazide. This drug is prescribed for the treatment of acute bacterial diarrhea in adults and children from one month of age.

Стопдиар acts locally within the intestine, targeting specific bacteria responsible for diarrhea without disrupting the gut's normal microflora. The medication is designed to work primarily within the gastrointestinal tract, with minimal absorption into the bloodstream. It aims to help restore microbial balance during bacterial infections and prevent secondary bacterial complications in viral infections.

Patients are advised to maintain adequate fluid intake to prevent dehydration during treatment. The drug is contraindicated for newborns under one month old and premature infants. Gedeon Richter urges individuals to seek medical attention if symptoms do not improve within three days or if signs of severe illness, such as fever or signs of intoxication, emerge. Concurrent use with certain medications, including disulfiram-like reaction-inducing drugs and CNS depressants, should be avoided. Alcohol consumption is also prohibited during treatment due to potential severe reactions.

The information also covers usage during pregnancy and breastfeeding, recommending consultation with a healthcare professional. Стопдиар does not affect the ability to drive or operate machinery. The medication contains sucrose, which patients with sucrose intolerance should consider, with dosage information provided in bread units (HE).